Frontlight ResearchEarly access
Taking people in United StatesPhase 2
Study of Tirzepatide for Recovery and Alcohol Use Management
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Boston and Jamaica Plain, United StatesSee the 2 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 15 Sept 2025
- Expected to end
- 1 Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Tirzepatide
- Saline Placebo
- Record updated
- 9 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- English speaking adults aged 18 and above
- Diagnosed with current DSM-5 alcohol use disorder
- Willing and able to physically travel to BWH CCI outpatient facilities for study visits
Who cannot take part
- Use of any GLP-1 agonist medications in the prior 3 months
- Anticipating receipt of any other GLP-1 agonist medications during the trial
- Anticipated to be enrolled in another clinical drug trial during participation in this trial
- Psychotic disorder, active suicidality or homicidality or any psychiatric condition that impair ability to provide informed consent
- Any lifetime diagnosis of eating disorders including anorexia, bulimia, binge eating, or avoidant/restrictive food intake disorder
- Current or lifetime diagnosis of Type 1 or Type 2 diabetes
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- Untreated cholelithiasis or gallbladder disease
- Acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, or congestive heart failure in the last 90 days
- Uncontrolled hypertension at baseline, as indicated by an average blood pressure reading of >180/110 after three successive readings
- History of inflammatory bowel disease, bariatric surgery, pancreatitis, diabetic gastroparesis, or non-arteritic anterior ischemic optic neuropathy
- History of hypersensitivity or allergy to tirzepatide
- Any other reason or clinical condition that the investigators judge may interfere with study participation and/or be unsafe for a participant
- Current (or within 30 days of enrollment) use of any anti-obesity medications or medications with glucose lowering properties (including GLP-1 analogues, sulfonylurea, insulin, metformin, thiazolidinediones, dipeptidyl peptidase-4 (DPP-IV) inhibitors, or sodium-glucose cotransporter-2 (SGLT-2) inhibitors)
- Current hypoglycemia as indicated by a blood sugar level of ≤70 mg/dL measured at the baseline visit
- Triglycerides ≥500 mg/dL
- Renal impairment as indicated by eGFR of <30
- CIWA score at screening ≥ 8
- BMI<23 mg/kg2
- Calcitonin ≥ 50 ng/L
- Liver function test greater than 5 times upper normal limit
- Pregnant or breastfeeding
This trial is currently available in United States.
- Brigham and Women's HospitalBoston, United StatesContact: Joji Suzuki, MDNo longer taking part
- Brigham and Women's Faulkner HospitalJamaica Plain, United StatesContact: Joji Suzuki, MDTaking people
About the trial
What the trial wants to find out
This is a pilot, 4-week, double-blind, placebo-controlled, randomized trial of individuals with alcohol use disorder (AUD) to receive weekly injections of either tirzepatide (n=10) or matching placebo (n=10). The primary aim is to determine the effects of tirzepatide on cue-reactivity among individuals with AUD. The secondary aim is to assess the safety and preliminary efficacy of tirzepatide for AUD.
The 2 groups in the trial
- TirzepatideTreatment being tested
This arm will receive tirzepatide (n=10) weekly 2.5mg injections for 4 weeks.
- Saline PlaceboPlacebo, for comparison
This arm will receive saline placebo injections (n=10) weekly for 4 weeks.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Tirzepatide for the Treatment of Alcohol Use Disorder: A Pilot Randomized Controlled Trial
- Record updated
- 9 July 2026